
Boehringer Ingelheim Launches Open-Access Platform of Selected Preclinical Molecules
The opnME.com platform offers scientists access to best-in-class molecules supported by comprehensive data packages.
Boehringer Ingelheim
The molecules on opnMe.com fall in two categories, offered under different terms. Most of the molecules can be accessed via a simple shopping cart system, without having to enter into intellectual property discussions. For selected molecules, a crowdsourcing option offers the opportunity to initiate joint research projects. Those interested are invited to submit a research proposal for molecules in this group and if the proposal is selected, the science will be developed together with scientists from Boehringer Ingelheim.
This launch is part of Boehringer Ingelheim’s ongoing mission to further scientific research and medical progress through collaboration and innovation. The company has started other similar initiatives including Research Beyond Borders and the Boehringer Ingelheim Venture Fund, which are part of the company’s long-standing and continuing work in core therapeutic areas of cardiometabolic diseases, respiratory diseases, oncology, central nervous system diseases, and immunology.
“Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas,” said Clive R. Wood, PhD, senior corporate vice-president, Discovery Research at Boehringer Ingelheim, in a
Wood invites interested scientists worldwide to visit opnMe.com to access the company’s molecules. “We will measure the success of this initiative in terms of new experiments, publications, and relationships forged,” he commented in the same
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.